JP2010526068A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526068A5
JP2010526068A5 JP2010506314A JP2010506314A JP2010526068A5 JP 2010526068 A5 JP2010526068 A5 JP 2010526068A5 JP 2010506314 A JP2010506314 A JP 2010506314A JP 2010506314 A JP2010506314 A JP 2010506314A JP 2010526068 A5 JP2010526068 A5 JP 2010526068A5
Authority
JP
Japan
Prior art keywords
itpp
composition
inositol
tripyrophosphate
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526068A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/005603 external-priority patent/WO2008134082A1/en
Publication of JP2010526068A publication Critical patent/JP2010526068A/ja
Publication of JP2010526068A5 publication Critical patent/JP2010526068A5/ja
Pending legal-status Critical Current

Links

JP2010506314A 2007-05-01 2008-05-01 エリスロポエチン補完または置換 Pending JP2010526068A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92705907P 2007-05-01 2007-05-01
PCT/US2008/005603 WO2008134082A1 (en) 2007-05-01 2008-05-01 Erythropoietin complementation or replacement

Publications (2)

Publication Number Publication Date
JP2010526068A JP2010526068A (ja) 2010-07-29
JP2010526068A5 true JP2010526068A5 (enExample) 2012-07-12

Family

ID=39926016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506314A Pending JP2010526068A (ja) 2007-05-01 2008-05-01 エリスロポエチン補完または置換

Country Status (7)

Country Link
US (2) US20080312138A1 (enExample)
EP (1) EP2152085A4 (enExample)
JP (1) JP2010526068A (enExample)
CN (1) CN101784193A (enExample)
AU (1) AU2008246061A1 (enExample)
CA (1) CA2688233A1 (enExample)
WO (1) WO2008134082A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266668A1 (en) * 2010-12-01 2013-10-10 Virginia Commonwealth University Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
US10159688B2 (en) 2013-03-15 2018-12-25 M. Alphabet 3, L.L.C. Methods and compositions for enhancing oxygen levels in tissues
WO2015138916A1 (en) * 2014-03-14 2015-09-17 Yves Claude Nicolau Myo-inositol trispyrophoshate as an anti-diabetic agent
CN111714504A (zh) * 2020-06-08 2020-09-29 广州新民培林医药科技有限公司 Itpp在制备预防和/或治疗缺血缺氧损伤及肺损伤的药物中的应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192869A (en) * 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPS5828878B2 (ja) * 1980-08-20 1983-06-18 三金工業株式会社 環状ピロ燐酸エステル誘導体
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4478824A (en) * 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5545632A (en) * 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
US5023248A (en) * 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US5407924A (en) * 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
US5015634A (en) * 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
US4887995A (en) * 1985-01-22 1989-12-19 University Of Pittsburgh Method of treating sickle cell anemia
US5292913A (en) * 1986-03-11 1994-03-08 Mitsui Toatsu Chemicals, Incorporated Myoinositol derivatives and preparation process thereof
WO1987005598A1 (fr) * 1986-03-11 1987-09-24 Mitsui Toatsu Chemicals, Incorporated Derives de myoinositol et procede de preparation
US4699926A (en) * 1986-04-04 1987-10-13 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
US4751244A (en) * 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731473A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US5057507A (en) * 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US5135923A (en) * 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
US5274161A (en) * 1986-11-26 1993-12-28 Perstorp Ab Derivatives of cyclohexane
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4924023A (en) * 1987-05-29 1990-05-08 E. I. Du Pont De Nemours And Company Phosphorylated inositols
US4873355A (en) * 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
US4931276A (en) * 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US4826675A (en) * 1988-02-17 1989-05-02 Colgate-Palmolive Company Anticalculus oral composition
US5043261A (en) * 1989-04-10 1991-08-27 Cryopharm Corporation Lyophilized and reconstituted red blood cell and hemosome compositions
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US4874690A (en) * 1988-08-26 1989-10-17 Cryopharm Corporation Lyophilization of red blood cells
EP0431197A4 (en) * 1989-06-28 1991-12-04 Mitsui Toatsu Chemicals Inc. Myoinositol derivative and method of production thereof, and phosphorylating agent and its use
US5151539A (en) * 1989-07-03 1992-09-29 Akzo America Inc. Formation of tetraarylpyrophosphate
EP0445299A4 (en) * 1989-09-22 1992-03-18 Mitsui Toatsu Chemicals, Inc. Inositol derivative and production thereof
JPH03115290A (ja) * 1989-09-28 1991-05-16 Yokohama Rubber Co Ltd:The １ｄ―ミオイノシトール―１―リン酸の合成法
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
US5210263A (en) * 1990-05-15 1993-05-11 University Of Pittsburgh Inositol phosphate analogs and methods for their use
US5295944A (en) * 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
US5260472A (en) * 1992-01-29 1993-11-09 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Efficient chemoenzymatic synthesis of D-myo-inositol 1,4,5-triphosphate, D-myo-inositol 1,3,4-triphosphate, and D-myo-inositol 1,3,4,5-tetraphosphate
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5260287A (en) * 1992-05-11 1993-11-09 Board Of Regents, The University Of Texas System Polyphosphorylated organic compounds: compositions useful in protecting biological tissues
KR960700740A (ko) * 1993-03-23 1996-02-24 라차아드 엘 콘 세포내 생물학적 활성 물질의 캡슐화 방법 및 장치(method and apparatus for encapsulation of biologic ally-active substances in cells)
US5866548A (en) * 1993-04-09 1999-02-02 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
US5827837A (en) * 1993-08-20 1998-10-27 The Regents Of The University Of California Polyanion anti-inflammatory agents
SE502989C2 (sv) * 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av läkemedel
SE503122C2 (sv) * 1993-11-22 1996-03-25 Perstorp Ab Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
US6074605A (en) * 1995-03-10 2000-06-13 Entremed, Inc. Flow electroporation chamber and method
US5720921A (en) * 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US6949517B1 (en) * 1996-06-24 2005-09-27 Matti Siren Method of treating inflammatory, tissue repair and infectious conditions
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
US6096916A (en) * 1997-05-23 2000-08-01 Nutrimed Biotech Synthesis of D-3 phosphorylated phosphoinositides and analogues
US6187335B1 (en) * 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US7410941B1 (en) * 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
DE50104611D1 (de) * 2000-04-12 2004-12-30 Bitop Ag Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US6610702B2 (en) * 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
WO2002009723A2 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
JP2004518639A (ja) * 2000-11-21 2004-06-24 イノロジック， インコーポレイテッド 塩化物分泌を増加しそして炎症を阻害するためのイノシトール誘導体
WO2002070009A1 (en) * 2001-02-27 2002-09-12 Yasuda, Yoshiko Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
WO2002072788A2 (en) * 2001-03-14 2002-09-19 Centocor, Inc. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
US20050020542A1 (en) * 2001-09-20 2005-01-27 Alexis Traynor-Kaplan Method of modulating sodium ion absorption in epithelial cells
CA2488230C (en) * 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
WO2004002403A2 (en) * 2002-06-14 2004-01-08 Gmp Oxycell, Inc. Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CA2520291A1 (en) * 2003-03-27 2004-10-14 Inologic, Inc. Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US20070135389A1 (en) * 2004-07-06 2007-06-14 Claude Nicolau Tumor eradication by inositol-tripyrophosphate
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
JP5028405B2 (ja) * 2005-03-18 2012-09-19 ノームオクシス インコーポレイテッド ヘモグロビンのアロステリックエフェクターとしてのミオイノシトール１，６：２，３：４，５トリピロリン酸のカルシウム塩
CA2674048A1 (en) * 2006-12-29 2008-07-10 Normoxys, Inc. Cyclitols and their derivatives and their therapeutic applications

Similar Documents

Publication Publication Date Title
Rawal et al. Anemia in intensive care: a review of current concepts
CN105380936A (zh) 铁代谢改善剂
AU2011329088B2 (en) Methods for enhancing oxygenation of jeopardized tissue
JP2018507260A5 (enExample)
Diehl et al. Use of continuous renal replacement therapy for treatment of dogs and cats with acute or acute‐on‐chronic renal failure: 33 cases (2002–2006)
US20180185443A1 (en) Kit for treating sepsis and/or any systemic (sirs) or damaging cellular hyperinflammation
Asare Anemia of critical illness
Levin et al. Healing of refractory leg ulcer in a patient with thalassemia intermedia and hypercoagulability after 14 years of unresponsive therapy
US20110294732A1 (en) Erythropoletin complementation or replacement
CN115300509B (zh) 罗沙司他治疗难治性贫血的应用
Arıcan et al. Clinical comparison of medetomidine with isoflurane or sevoflurane for anesthesia in horses.
Schmid et al. New strategies for managing anemia of chronic kidney disease
Vadehra et al. Treating a patient with your hands tied: acute chest syndrome in a Jehovah's witness
CN101708184B (zh) 铁脂质体的药物应用
AU2014264537B2 (en) Dialysis formulation
Liao et al. Successful large-volume leukapheresis for hematopoietic stem cell collection in a very-low-weight brain tumor infant with coagulopathy
Fishbane et al. Roxadustat Lowers Risk of Red Blood Cell Transfusion in Patients with Anemia of CKD: PO0256
Kopparthy et al. Red blood cell exchange in a patient with extramedullary hematopoiesis and cor pulmonale secondary to beta thalassemia
He et al. High-risk end-stage renal disease patients converted from conventional to short daily haemodialysis
EP2609915B1 (en) Dialysis and substitution fluid
Pieri et al. Impact of cytosorb treatment on drugs’ need in critically ill patients
Rostami et al. Managing Systemic Complications in Dialysis
Sharandak et al. Myocardium dystrophy of highly producing cows
Hoffman et al. Triferic (Ferric Pyrophosphate Citrate, FPC) Maintains Hemoglobin and Reduces IV Iron: Results from a Single-Site 2-Year Observational Analysis: PO0255
RU2475234C2 (ru) Способ профилактики тяжелых осложнений при хирургическом лечении массивных и субмассивных кровопотерь с продолжающимся кровотечением